Balfaxar receives FDA nod for treating acquired coagulation factor deficiency
Octapharma USA has announced the US Food and Drug Administration (FDA)’s approval of Balfaxar (prothrombin complex concentrate, human-lans), a treatment for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy. This approval marks a new opportunity for adult patients who urgently need surgery or invasive procedures. Balfaxar, a […]